Home
   Links
   Faculty Information
   Activities & Events
   Melanoma Care Centers
 
   Slide Library
   Polling Results
   Patient Resources
 
   Contact Us
   Register
   Log-in
   
 
 
 
 
 
 
 
 
 
Log In

Activity:

Scientific and Clinical Interpretation of New Data on IFN-a for Adjuvant Therapy of Melanoma

CME Course Duration:

Start Date: April 2009
End Date: April 2010

Speaker:
John M. Kirkwood, MD
Director, Melanoma and Skin Cancer Center
Professor and Vice Chairman for Clinical Research
University of Pittsburgh School of Medicine
Pittsburgh, PA



Featured Topic Information:
Please click here to view a webcast (registration required)
Please click here to view the slide library (registration required)
Please click here to listen to the audio (registration required)
Please click here to take the post test and evaluation (registration required)
Please click here if you have any comments or questions relating to this topic

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who treat or screen for melanoma.

Educational Objective

Interpret the latest data on various adjuvant interferon (IFN) alfa-2b regimens and extrapolate these findings to clinical practice

Faculty Disclosure Statement

Dr. John M. Kirkwood has disclosed he has participated on the speaker’s bureau for Schering-Plough Corporation; serves as a consultant to Eleos, Inc., and has received grant/research support from Schering-Plough Corporation, Berlex Laboratories, and Pfizer, Inc.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.